ArticleProceedings. IEEE International Conference on Bioinformatics and Biomedicine2024
An application of studying FAERS data to Enhance Drug Safety and Treatment Outcomes in Rare Diseases.
Article in Proceedings. IEEE International Conference on Bioinformatics and Biomedicine, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Rare diseases affect fewer than 200,000 individuals in the United States, with some being so rare that only a handful of people are impacted. According to the U.S. Food and Drug Administration (FDA), there are 1,268 approved orphan drugs available for treating these conditions. However, potentially beneficial drugs can also have side effects. Some adverse events, while serious, may be rare, making them difficult to identify or quantify in randomized controlled trials. Understanding these events is critical for improving patient safety and treatment outcomes. To better assess these risks, we aimed at summarizing adverse drug events for rare diseases by utilizing FDA Adverse Event Reporting System (FAERS). This study offers a foundation for future research of improving drug safety in rare diseases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.